Tempus AI (TEM) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Tempus AI

NasdaqGS•Healthcare•Health Information Services

$62.21+3.20(0.05%)After hours

Market Cap

$14.00M

P/S

0.0x

P/B

0.0x

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

How this company scores

WeakMetricSide Score: 53/100

Grade capped at D — Interest coverage below 1× (-6.9x) — earnings cannot cover interest. Strongest: Growth (18/25); weakest: Cash & Earnings Quality (6/25).

Profitability12/25

Growth18/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality6/25

Strengths

Growing revenueLong cash runwayLow leverageImproving leverage

Grade capped at D

Interest coverage below 1× (-6.9x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.0x5y range 0.0x – 0.0x

Currently near its 6-quarter median.

P/B · 0.0x5y range 0.0x – 0.2x

Currently near its 9-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $14.00M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.43B
Q. Revenue: $382.49M
TTM EBITDA: $-176.93M
TTM Op. Income: $-283.03M
Q. Op. Income: $-75.91M
TTM Net Income: $-254.43M
Q. Net Income: $5.64M
EPS: $0.03
Shares Out.: $179,917

$1.43B in TTM revenue grew 30.4% YoY, reaching $382.49M last quarter. TTM EBITDA of $-176.93M and TTM operating income of $-283.03M show growth is flowing through to the bottom line. However, net income is negative at $254.43M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 64.4%
EBITDA Margin: -13.1%
Op. Margin: -19.8%
Net Margin: 1.5%

Op. margin of -19.8% is down 0.2% YoY — costs are rising relative to revenue. Net margin at 1.5% and gross margin of 64.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 1% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.0x
P/B Ratio: 0.0x

P/S of 0.0x and P/B of 0.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.37B
Cash: $599.61M
Long-Term Debt: $187.93M
Book Value: $444.93M
D/E Ratio: 0.4
Debt/EBITDA: N/A

With $2.37B in assets and $187.93M in long-term debt, D/E is 0.4and book value is $444.93M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 42% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-7.53M
TTM Free Cash Flow: $-263.22M
FCF Margin: -18.4%
FCF / Net Income: 1.0

TTM FCF of $-263.22M on $-7.53M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 278% — a weakening trend.